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Bcl-2 and p53 protein expression in all grades of astrocytomas 
By: Robyn L. Castleberg 
Research in Biology 
November 1994 
An astrocyte is a brain cell which produces processes that attach to blood vessels and act 
as supporter cells to the brain parenchyma. However, if these cells undergo transformation they 
are no longer referred to as astrocytes, but instead are labeled astrocytomas. These tumor cells 
are classified as Intercranial Tumors (origin is the brain) and are diagnosed according to 
their severity. The diagnoses range from low-grade astrocytomas (World Health Organization or 
WHO, grade I or II), which grow slowly and may have a latent period, to fast-growing anaplastic 
astrocytomas (WHO grade ill) and glioblastoma multiforme (GBM, WHO grade IV), which 
produce fatal effects much faster(Henson, in press). A principle feature of astrocytomas is 
progression toward more malignant forms. Therefore, though grade II astrocytomas seem to 
have the best prognosis they too will eventually produce rapidly enlarging lesions with anaplastic 
histological features. This proclivity of all grades of astrocytomas to move towards anaplasia is 
the reason for the poor clinical outcome of patients with astrocytomas(Henson, in press). 
Due to the poor prognosis of all types of astrocytomas, treatments such as radiation and 
chemotherapy have been used to significantly detour the final result of this primary intracranial 
tumor. However, sometimes these treatments fail to elicit the desired results and the 
astrocytomas either do not respond to treatment or produce a resistant cell population upon 
relapse ofthe originally responsive astrocytoma(Lowe 1993). Consequently, many experimental 
studies have begun to look at the underlying basis of cellular resistance to anticancer agents. For 
example, the recent discovery of the bcl-2 (B-celllymphoma type II) gene and its derivative 
protein is helping to answer the question of why some cells with DNA damage or deregulated 
proliferations are not following the expected apoptotic (programmed cell death) pathway. 
The bcl-2 gene, discovered in follicular B-celllymphomas and found in cell lines which are 
characterized by apoptotic cell turnover, produces an inner mitochondrial membrane protein 
(Hockenbury 1991). Moreover, when the bcl-2 protein is overexpressed it counteracts the wild-
type (normal) p53 protein, which initiates apoptosis (Louis 1994). The resulting suppression of 
the p53 protein allows the cell to become immortalized, anaplastic, or genomically instable, which 
produces prime conditions for oncogenesis (Figure 1) (Louis 1994). These results indicate the 
importance ofbcl-2 in the survival of tumor cells and suggest one reason why some cells are 
resistant even after anticancer agents have damaged cellular DNA or other apoptotic initiators. 
Accordingly, understanding the mechanism or catalyst which oncogenic cells use to initiate 
overproduction ofbcl-2 and inactivation of p53 may determine the success of cancer therapy. 
In light of the above understanding of the interaction between bcl-2, p53, and apoptosis, 
scientists have examined many tumor tissues (breast, skin, prostate, etc.) looking for the 
expression ofbcl-2 (Hockenbury 1991). However, one oncogenic tissue on which bcl-2 
expression has not been researched is the astrocytoma. Therefore, in order to see ifbcl-2 is 
overexpressed in astrocytomas foregoing apoptosis and ifbcl-2's expression is related to the type 
ofp53 present (wild type or mutant), both bcl-2 and p53 immunohistochemistry were performed 
on all grades of astrocytomas. Also, single stranded conformational polymorphism (SSCP) was 
performed on the p53 gene from each case to determine if it was mutant or wild type. 
METHODS AND MATERIALS 
Cases. All tumors were cerebral hemispheric astrocytomas from adults that were classified, 
according to the WHO criteria, by a neuropathologist, David N. Louis. One case was WHO 
grade I, five cases were WHO grade II, twelve cases were WHO grade m, and eleven cases were 
WHO grade IV or GBM. All cases were from primary resection specimens. Paraffin embedded 
tissue was available for immunohistochemistry on all cases and tumor DNA was available for 
single stranded conformational polymorphism (SSCP). 
Immunohistochemistry. 6-urn sections of paraffin embedded tumors were cut with a microtome 
and were heat-fixed unto Poly-L-lysine coated slides. The paraffin was removed using xylene and 
the tissue was rehydrated with ethanol. Sections used for p53 staining were blocked with normal 
horse serum and incubated with p53 antibodies (P Ab 1801 Oncogene Sci), diluted I: I 000, 
overnight at 4°C. The sections were then exposed to biotinylated horse anti-mouse lgG and 
Streptavidin-horseradish peroxidase (ABC reagent) followed by diaminobenzidine (Vectastain 
DAB Kit), which stains antibodies brown, and methyl green (a green counterstain to 
diaminobenzidine). Sections for bcl-2 staining were boiled in sodium-citrate (pH 6) for 15 
minutes, blocked with normal horse serum, and incubated with bcl-2 antibodies (Dako), diluted 
1 :250, overnight at 4°C. Biotinylated horse anti-mouse IgG and ABC reagent were then applied 
to the sections, and diaminobenzidine solution and methyl green staining followed, respectively. 
Controls were performed for both p53 and bcl-2 by omitting the primary antibody and by staining 
tissue sections of oncogenic human lymphnode as positive and negative controls. The slides were 
evaluated for the presence and proportion of positively stained cells and for the subcellular 
localization of the reaction product by a neuropathologist, David N. Louis. 
SSCP Analysis. SSCP was performed as described (Louis et. al. 1993), and exons 5 through 8 
of the p53 gene were amplified from tumor DNA using PCR conditions and oligonucleotides 
according to protocol (Louis et. al. 1993). The amplification products were separated on 6% 
non-denaturing polyacrylamide gels with 10% glycerol overnight at 4 Watts. The gels were dried 
and exposed to autoradiography film. 
RESULTS: 
bcJ-2 and p53 protein expression in astrocytomas. 
To determine whether the 29 astrocytomas express the protein bcl-2 and p53, these 
tumors were studied with immunohistochemistry using two antibodies, anti-bcl-2 (Daleo) and anti-
p53 (PAb 1801 Oncogene Sci). Anti-bcl-2 (Daleo) is a monoclonal mouse antibody which reacts 
specifically with the integral membrane bcl-2 oncoprotein located in the mitochondria (DAKO 
Specification Sheet). Positive reaction was observed only in cytoplasm and varied in intensity and 
population, with some cytoplasm staining stronger and/or more frequently than others (Fig. 2). 
Furthermore, all but one of the 29 cases stained positive for the bcl-2 protein (Table 1). 
To detect the p53 protein, the monoclonal antibody for p53 (PAb 1801 Oncogene Sci), 
which is human-specific for the NH2 terminus of both wild type and mutant p53 protein, was used 
(Rubio 1993). Irrununohistochemistry with Pab 1801 showed variable positive nuclear staining, 
with some nuclei staining darker than others (Fig. 3). Also, many of the astrocytomas did not 
show any staining and were therefore labeled negative (Table 1 ). 
The positive control lymphoma sections for both bcl-2 and p53 showed moderate to 
strong staining in the cytoplasm and nucleus, respectively (Fig. 4). Furthermore, the negative 
control lymphoma sections in which primary antibody was omitted or an irrelevant antibody was 
used, resulted in no irrununohistochemical reaction for either bcl-2 or p53 (Fig. 4). 
SSCP on p53 genes from all astrocytoma cases. 
SSCP analysis showed three cases to have mutations in an area between exon 5 and exon 
8 (Table 1). One case had a mutation in exon 6, a second case showed a mutation in exon 5, and 
a third case expressed a frameshift mutation at codon 262 (this frameshift was sequenced at an 
earlier time). The other 26 cases expressed wild-type amino acid sequences for exons 5-8. 
DISCUSSION 
Due to the significance of apoptosis to developmental processes, major interest has arisen 
in genes capable of regulating programmed cell death. One of the most important strides in our 
understanding of apoptotic cell death regulation in vertebrates has come from studies of the 
oncogene bcl-2 (Boise et. al. 1993). Overexpression ofbcl-2 protein blocks the programmed cell 
death, which means it also takes precedence over the p53 protein that plays a role in initiating 
apoptosis (Williams and Smith 1993). Furthermore, many different cell tissue types have 
expressed the bcl-2 protein, however, research on bcl-2 expression in astrocytomas had not 
transpired before now. 
In our study, we showed that bcl-2 protein is expressed in all grades of astrocytomas, 
whether p53 was or was not present. To begin our research, we performed 
immunohistochemistry on lymphoma sections which were known to positively express p53 and 
bcl-2 protein. This allowed for fine-tuning of both immunohistochemical procedures before 
astrocytomas sections were used. In the procedural testing on p53, it was found that the best 
staining occurred when the diaminobenzidine from the Vectastain DAB Kit was used in place of 
the Working DAB solution, and when the biotinylated horse-anti-mouse antibody was diluted 
1:400 instead of 1:500 (which the original procedure required). After the protocol for p53 was 
determined, work on the bcl-2 procedure began. 
Like p53, the bcl-2 protocol also required some changes in order to improve staining. 
The first lymphomas stained for bcl-2 produced high background staining and therefore the 
dilutions of primary antibody were adjusted. It was found that the primary antibody (anti-bcl-2) 
diluted 1:250 worked much better than the original dilution of 1:40. After this adjustment was 
made, ~he background staining was virtually eliminated. However, because some cases persisted 
in showing slight background staining, a primary antibody was added to the control tissues in 
order to show anti-bcl-2 (Dako) was actually staining bcl-2 protein and not some other element. 
The primary antibody used on the controls was anti-Large T antibody. Its use did not change the 
staining pattern and therefore supported the effectiveness of anti-bcl-2 (Dako) in recognizing the 
bcl-2 protein. 
Though both of the procedures were modified to give the best results, there were still two 
cases which were unidentifiable after the procedural changes were implemented. Both cases had 
an excessive amount of background staining and therefore made it impossible to accurately 
estimate either p53 or bcl-2 expression. Because immunohistochemistry did not yield any results 
on these two cases, it was decided not to perform SSCP on their p53 genes. 
After the immunohistochemistry results were known for both p53 and bcl-2 on all twenty-
nine cases, SSCP was performed on the p53 gene from the twenty-seven identifiable cases. If the 
p53 gene was wild type, then it would be able to perform apoptosis. However, if it were mutant 
it would not be able to initiate apoptosis (Louis 1994). Therefore, in cases expressing mutant 
p53, bcl-2 overexpession would not be expected because the cell can not initiate programmed cell 
death with mutant p53 . 
The SSCP results on exons 5 through 8 showed the p53 gene was mutant in three cases. 
When this information was compared to the bcl-2 results it was found that when p53 was wild 
type, bcl-2 was usually overexpressed in more than two-thirds of all the astrocytomas in that case. 
However, it was found that the three mutant p53 cases expressed bcl-2 in less than one-third of 
all the astrocytomas in each specific section (Table 1 ). Therefore, these results help support the 
conclusion that bcl-2 is not greatly overexpressed when p53 is mutant. 
In this research project, new information on astrocytomas was obtained. Our findings 
added astrocytomas to the list of tissues expressing bcl-2 and they suggest that bcl-2 expression 
may be controlled by the type ofp53 present. Bcl-2 seems to be overexpressed when p53 is wild 
type, but when p53 is mutant, bcl-2 is minimally expressed in the astrocytoma section. Though 
this research has furthered scientists' understanding ofbcl-2, p53, and astrocytomas, more studies 
need to be performed to better establish our findings. 
One such study, which I feel would be beneficial, would be to conduct research on what 
types of cancer treatments induce the most bcl-2 protein. To do this for astrocytomas, one would 
need to evaluate different tissue sections which are similar in most aspects but differed in the type 
of treatment (radiation, chemotherapy, etc.). Along with this study, it would be advantageous to 
evaluate other tumor tissues to see if there is any difference between astrocytomas and other 
cancer types. When completed, this study would allow physicians to chose the best treatment 
plan for their patient. It would also further scientist's knowledge about cancer which would move 
the medical world one step closer to finding a cure for cancer. 
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TABLE 1. Classification, Expression and mutation analysis 
WHO BCL-2 p53 p53 
CASE GRADE 
89-28352 ++ Negative Wild type 
88-26986 ++ + Wild type 
90-34678 + + Wild type 
87-478 + Negative Wild type 
89-22294 + Negative Wild type 
87-33259 +++ Negative Wild type 
86-26634 + +++ Exon 5, codon 175 
+ + Exon 6, codon 
+ Negative Frameshift, codon 262 
89-21194 ++ +++ Wild type 
++ +++ Wild type 
++ Negative Wild type 
88-1488 +++ ++ Wild type 
+++ Negative Wild type 
91-28446 +++ +++ Wild type 
+++ Negative Wild type 
87-13945 ++ Negative Wild type 
88-25325 Unidentifiable Unidentifiable mutations in Exons 5-6 
GBM ++ Negative Wild type 
GBM +++ ++ Wild type 
GBM ++ +++ type 
91-2476 GBM +++ Negative type 
GBM + Negative Wild type 
GBM ++ Negative Wild type 
89-7192 GBM +++ Negative Wild type 
GBM + Negative Wild type 
89-29395 GBM Negative Negative Wild type 
GBM + Negative Wild type 
GBM Unidentifiable Unidentifiable No shifts 
+ less than 1/3 expression 
++ between 1/3 and 213 expression 
+++ More than 2/3 expression 
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Figure 1. Normal functions of wild-type p53 (top) and probable abnormal 
functions of mutant p53 (bottom) (Louis 1994). 
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Figure 2. Immunohistochemistry on paraffin-embedded astrocytomas for bcl-2. Astrocytomas 
grade demonstrating abundant bcl-2 staining of the cytoplasm in tumor cells (top) and 
glioblastoma multiforme showing moderate bcl-2 staining in the cytoplasm (bottom) 
Figure 3. Immunohistochemistry on paraffin-embedded astrocytomas for p53. A moderate 
amount of p53 nuclear staining is expressed in the tumor cells of this astrocytoma grade 
Ill) 
Figure 4. Immunohistochemistry on paraffin-embedded lymphomas and astrocytomas for bcl-2. 
Lymphomas incubated with an irrelevant antibody demonstrates no cytoplasmic staining (top left). 
Lymphoma showing positive bcl-2 staining in the cytoplasm of tumor cells (top right). 4C. bcl-2 
positive astrocytoma grade incubated with an irrelevant antibody expresses no 
cytoplasmic staining (bottom) ( All 
